NEW YORK, Nov. 14 – Orchid BioSciences said Wednesday it had agreed to collaborate with GlaxoSmithKline on a genome-wide SNP-validation program.

Under the terms of the deal, Glaxo will select SNP candidates from Orchid’s database and Orchid will provide high-throughput genotyping information. In addition, Orchid will also develop SNP assays for use in the genome-wide study. 

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.